Vericel’s Expanding Surgeon Base Drives MACI Growth

Vericel reported 2Q23 orthopedic sales of $36.3 million, +27% compared to the second quarter of 2022. For the first half of 2023, the company generated $70.5 million in orthopedic sales, +29.1% compared to the first half of the prior year.

An expanding surgeon base drove sustained growth for the company's MACI cartilage repair implant....

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

ME

Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.



Contact Us

0